Response of refractory anemia to low-dose cytosine arabinoside.

Two elderly patients with transfusion-dependent refractory anemia due to myelodysplastic syndromes were treated with a course of low-dose subcutaneous cytosine arabinoside in an attempt to reduce their transfusion requirements. Following treatment, they required no transfusions for over six months. The treatment was well tolerated, but was associated with initial myelosuppression.
AuthorsJ H Gallo, M C Rozenberg
JournalAustralian and New Zealand journal of medicine (Aust N Z J Med) Vol. 16 Issue 2 Pg. 231-3 (Apr 1986) ISSN: 0004-8291 [Print] AUSTRALIA
PMID3463278 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Cytarabine
  • Aged
  • Anemia, Refractory (blood, drug therapy, therapy)
  • Blood Cell Count
  • Blood Transfusion
  • Cytarabine (administration & dosage, therapeutic use)
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Male

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: